A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00075231
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of this study is to determine whether a simplified lopinavir-ritonavir based therapy will continue to keep the viral load to very low levels after initial treatment with a combination of Kaletra® (lopinavir/ritonavir) plus Combivir® (lamivudine/zidovudine).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Proportion of subjects with a plasma HIV RNA level below 50 copies/mL at Week 96.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Fountain Valley Regional Hospital and Medical Center
🇺🇸Fountain Valley, California, United States